APA (7th ed.) Citation

TE, W., PB, J., BR, L., PJ, K., LD, P., Jr, M. D., . . . A, G. (2017). Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). American journal of hematology, 92(10), 1004. https://doi.org/10.1002/ajh.24824

Chicago Style (17th ed.) Citation

TE, Witzig, et al. "Long-term Follow-up of Chemoimmunotherapy with Rituximab, Oxaliplatin, Cytosine Arabinoside, Dexamethasone (ROAD) in Patients with Relapsed CD20+ B-cell Non-Hodgkin Lymphoma: Results of a Study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 Now Known as Academic and Community Cancer Research United (ACCRU)." American Journal of Hematology 92, no. 10 (2017): 1004. https://doi.org/10.1002/ajh.24824.

MLA (9th ed.) Citation

TE, Witzig, et al. "Long-term Follow-up of Chemoimmunotherapy with Rituximab, Oxaliplatin, Cytosine Arabinoside, Dexamethasone (ROAD) in Patients with Relapsed CD20+ B-cell Non-Hodgkin Lymphoma: Results of a Study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 Now Known as Academic and Community Cancer Research United (ACCRU)." American Journal of Hematology, vol. 92, no. 10, 2017, p. 1004, https://doi.org/10.1002/ajh.24824.